Monday, February 01, 2010

CIRM Clinical Trial and Biotech Industry Loan Plans Remain Veiled

With only two days remaining before this week's meeting of the board of directors of the California stem cell agency, still missing publicly are any details on proposals that appear to involve hundreds of millions of dollars in taxpayer funds.

The plans concernCIRM's fledgling $500 million biotech loan program and participaton in funding of clinical trials, which can cost hundreds of millions of dollars. The agenda for the CIRM board meeting, which begins Wednesday afternoon, contained only 46 words this morning on the proposals.

CIRM's latest lack of transparency comes only six days after a key state panel unanimously urged CIRM to be more open and accountable. Sphere: Related Content

No comments:

Post a Comment